* Diabetes: Secondary Complications, Regulation and Innovation
1–2 October 2013
Marriott Hotel
Regent's Park
London
This program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy. The event faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease.
- Contact
- John Collins
- Email
- jcollins@smi-online.co.uk
- Phone
- 020 7827 6734
- Website
- Conference website
Key reasons to attend
- Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors
- Utilise biomarkers and imaging for the development of novel therapies for diabetes
- Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes
- Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment
- Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors
- Review clinical results from the DEMAND study.